CRYO Cryo-Save

 

TIDMCRYO 
 
RNS Number : 6505G 
Cryo-Save Group NV 
04 February 2010 
 

4 February 2010 
 
Cryo-Save Group N.V. 
 
Arnoud van Tulder appointed Chief Executive 
 
Cryo-Save Group N.V. (AIM/Euronext: CRYO, "Cryo-Save" or "the Group"), Europe's 
leading stem cell bank, has appointed Arnoud van Tulder as Chief Executive 
Officer with effect from 1 May 2010. Arnoud, currently Chief Financial Officer 
of Cryo-Save, will succeed Marc Waeterschoot, who will remain on the Board as an 
Executive Director. 
 
Johan Goossens, Cryo-Save Chairman said: 
 
"Arnoud has already made a huge contribution to Cryo-Save as CFO, steering us 
through listing both on AIM and Euronext, embarking on a successful investment 
and acquisition strategy and taking us into sustained growth.  We look forward 
to his continued success as Chief Executive." 
 
Enquiries: 
 
+-------------------------------+----------------------------+ 
| Cryo-Save Group               |       + 31 (0) 575 548 998 | 
+-------------------------------+----------------------------+ 
| Marc Waeterschoot, Chief      |                            | 
| Executive                     |                            | 
| Arnoud van Tulder, Chief      |                            | 
| Financial Officer             |                            | 
+-------------------------------+----------------------------+ 
|                               |                            | 
+-------------------------------+----------------------------+ 
| Daniel Stewart & Company plc  |      + 44 (0) 20 7776 6550 | 
+-------------------------------+----------------------------+ 
| Simon Leathers / Emma Earl    |                            | 
+-------------------------------+----------------------------+ 
|                               |                            | 
+-------------------------------+----------------------------+ 
| College Hill                  |     + 44 (0) 20 7457 2020  | 
+-------------------------------+----------------------------+ 
| Adrian Duffield/Rozi Morris   |                            | 
+-------------------------------+----------------------------+ 
 
About Cryo-Save 
 
With more than 120,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world.  Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOABRGDDRBGBGGX 
 

Cryo-Save (LSE:CRYO)
Gráfica de Acción Histórica
De Feb 2025 a Mar 2025

Cryo-Save (LSE:CRYO)
Gráfica de Acción Histórica
De Mar 2024 a Mar 2025